Literature DB >> 17372024

T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells.

Andreas A Hombach1, Verena Schildgen, Claudia Heuser, Ricarda Finnern, David E Gilham, Hinrich Abken.   

Abstract

Recombinant TCRs confer specificity to T cells and trigger their activation. Receptors with Ab-derived binding domains have the advantages of MHC-independent Ag recognition and of targeting a variety of chemically different molecules. We explored the impact of the position of a defined epitope within the target molecule on the efficacy of receptor-mediated T cell activation. T cells were grafted with recombinant immunoreceptors that recognize either the membrane distal N or the proximal A3 domain of carcinoembryonic Ag (CEA). Upon binding to isolated, solid-phase immobilized CEA, receptor-mediated T cell activation correlates with the binding efficiency, irrespectively, of the epitope position. Upon binding to CEA expressed on the cell membrane, in contrast, the A3 epitope mediates more efficiently T cell activation than the N epitope, although the N epitope is bound with higher affinity. The CEA N epitope when expressed in a more membrane proximal position, however, activated receptor grafted T cells with higher efficiency than in the distal position. The position of the targeted epitope within the molecule obviously has major impact on the efficacy of T cell activation independently of the binding efficiency of the immunoreceptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372024     DOI: 10.4049/jimmunol.178.7.4650

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

2.  Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Authors:  Scott E James; Philip D Greenberg; Michael C Jensen; Yukang Lin; Jinjuan Wang; Brian G Till; Andrew A Raubitschek; Stephen J Forman; Oliver W Press
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv.

Authors:  E Faitschuk; V Nagy; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2016-06-14       Impact factor: 5.250

Review 4.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

5.  Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.

Authors:  Haiying Qin; Justin P Edwards; Liubov Zaritskaya; Ankit Gupta; C Jenny Mu; Terry J Fry; David M Hilbert; David W LaFleur
Journal:  Mol Ther       Date:  2019-04-17       Impact factor: 11.454

6.  Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Authors:  Kurt Schönfeld; Christiane Sahm; Congcong Zhang; Sonja Naundorf; Christian Brendel; Marcus Odendahl; Paulina Nowakowska; Halvard Bönig; Ulrike Köhl; Stephan Kloess; Sylvia Köhler; Heidi Holtgreve-Grez; Anna Jauch; Manfred Schmidt; Ralf Schubert; Klaus Kühlcke; Erhard Seifried; Hans G Klingemann; Michael A Rieger; Torsten Tonn; Manuel Grez; Winfried S Wels
Journal:  Mol Ther       Date:  2014-11-06       Impact factor: 11.454

Review 7.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

10.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.